Wheeler CJ et al. - In a study to evaluate the use of a glioblastoma multiforme (GBM) vaccine, it seems that there is a progressive correlation between cancer clinical outcome and T-cell responsiveness after therapeutic vaccination in humans and resulting from therapeutically exploitable tumor alteration. These findings offer unique opportunities to identify cellular and molecular components of clinically meaningful antitumor immunity in humans Methods
IFN-γ responsiveness was quantified in peripheral blood of 32 GBM pts given therapeutic dendritic cell vaccines
Posttreatment times to tumor progression (TTP) and survival (TTS) were compared in vaccine responders and nonresponders and were correlated with immune response magnitudes
Results
53% of GBM pts exhibited 1.5-fold vaccine-enhanced cytokine responses
Endogenous antitumor responses of similar magnitude occurred in 22% of GBM pts before vaccination
Vaccine responders exhibited significantly longer TTS and TTP relative to nonresponders
Immune enhancement in vaccine responders correlated logarithmically with TTS and TTP spanning postvaccine chemotherapy, but not with initial TTP spanning vaccination alone
See all
